PMID- 30661514
OWN - NLM
STAT- MEDLINE
DCOM- 20200221
LR  - 20200221
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Jan
TI  - Factors Affecting Early Death and Survival of Patients With Acute Promyelocytic 
      Leukemia Treated With ATRA-Based Therapy Regimens.
PG  - e63-e70
LID - S2152-2650(18)30270-2 [pii]
LID - 10.1016/j.clml.2018.08.001 [doi]
AB  - PURPOSE: To perform a retrospective analysis of the prognostic relevance of 
      clinicopathologic parameters in a well-documented cohort of patients treated with 
      all-trans-retinoic acid (ATRA)-based induction regimens in order to discover 
      which indicators can predict a high risk of early death (ED) and patient 
      survival. PATIENTS AND METHODS: We analyzed data of 288 newly diagnosed adult 
      acute promyelocytic leukemia patients in Hangzhou, China. The median follow-up 
      time was 32 months (range, 6-78 months). RESULTS: The 3-year disease-free and 
      overall survival rates were 90.83% and 91.69%, respectively. In the multivariable 
      analysis, older age (>/= 60 years) was the only independent risk factor for ED 
      (hazard ratio [HR] = 15.057; P = .004). High white blood cell count was not a 
      risk factor for ED (P = .055), but it was for relapse (HR = 2.7; P = .009). FLT3 
      mutation (HR = 3.9; 95% confidence interval, 1.4 to 10; P = .007) and older age 
      (>/= 60 years) (HR = 5.3; 95% confidence interval, 2.4 to 11; P < .001) were 
      prognostic factors for poorer disease-free and overall survival. Interestingly, 
      CD15 negativity (HR = 0.23; P = .049) was a prognostic factor for relapse. The ED 
      rate was 5.9% (17/288 patients). CONCLUSION: The perceived impact of the 
      identification of these high-risk factors should be described in order to decide 
      whether any modifications to treatment strategy should be entertained.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Sun, Jianai
AU  - Sun J
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Zhu, Jingjing
AU  - Zhu J
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Zhou, De
AU  - Zhou D
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Zhu, Lixia
AU  - Zhu L
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Yang, Xiudi
AU  - Yang X
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Xie, Mixue
AU  - Xie M
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Li, Li
AU  - Li L
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Huang, Xianbo
AU  - Huang X
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Zhu, Mingyu
AU  - Zhu M
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Zheng, Yanlong
AU  - Zheng Y
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Xie, Wanzhuo
AU  - Xie W
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Ye, Xiujin
AU  - Ye X
AD  - Senior Department of Haematology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Electronic 
      address: yxjsunny@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180811
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use
MH  - Death
MH  - Female
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tretinoin/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - CD15 immunotype
OT  - Early death
OT  - FLT3 mutation
OT  - Prognostic factors
OT  - Relapse
EDAT- 2019/01/22 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/01/22 06:00
PHST- 2018/03/14 00:00 [received]
PHST- 2018/07/27 00:00 [revised]
PHST- 2018/08/01 00:00 [accepted]
PHST- 2019/01/22 06:00 [entrez]
PHST- 2019/01/22 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
AID - S2152-2650(18)30270-2 [pii]
AID - 10.1016/j.clml.2018.08.001 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e63-e70. doi: 
      10.1016/j.clml.2018.08.001. Epub 2018 Aug 11.